1. In Vivo Efficacy of a "Smart" Antimicrobial Implant Coating.
- Author
-
Stavrakis AI, Zhu S, Hegde V, Loftin AH, Ashbaugh AG, Niska JA, Miller LS, Segura T, and Bernthal NM
- Subjects
- Animals, Anti-Bacterial Agents administration & dosage, Colony Count, Microbial, Disease Models, Animal, Mice, Minocycline administration & dosage, Minocycline therapeutic use, Prosthesis-Related Infections drug therapy, Prosthesis-Related Infections microbiology, Staphylococcal Infections drug therapy, Staphylococcal Infections prevention & control, Staphylococcus aureus growth & development, Surgical Wound Infection drug therapy, Surgical Wound Infection microbiology, Tigecycline, Vancomycin administration & dosage, Absorbable Implants, Anti-Bacterial Agents therapeutic use, Minocycline analogs & derivatives, Prosthesis-Related Infections prevention & control, Staphylococcus aureus drug effects, Surgical Wound Infection prevention & control, Vancomycin therapeutic use
- Abstract
Background: Postoperative infection is a devastating complication following arthroplasty. The goals of this study were to introduce a "smart" implant coating that combines passive elution of antibiotic with an active-release mechanism that "targets" bacteria, and to use an established in vivo mouse model of post-arthroplasty infection to longitudinally evaluate the efficacy of this polymer implant coating in decreasing bacterial burden., Methods: A novel, biodegradable coating using branched poly(ethylene glycol)-poly(propylene sulfide) (PEG-PPS) polymer was designed to deliver antibiotics both passively and actively. In vitro-release kinetics were studied using high-performance liquid chromatography (HPLC) quantification in conditions representing both the physiologic environment and the more oxidative, hyperinflammatory environment of periprosthetic infection. The in vivo efficacy of the PEG-PPS coating delivering vancomycin and tigecycline was tested using an established mouse model of post-arthroplasty infection. Noninvasive bioluminescence imaging was used to quantify the bacterial burden; radiography, to assess osseointegration and bone resorption; and implant sonication, for colony counts., Results: In vitro-release kinetics confirmed passive elution above the minimum inhibitory concentration (MIC). A rapid release of antibiotic was noted when challenged with an oxidative environment (p < 0.05), confirming a "smart" active-release mechanism. The PEG-PPS coating with tigecycline significantly lowered the infection burden on all days, whereas PEG-PPS-vancomycin decreased infection on postoperative day (POD) 1, 3, 5, and 7 (p < 0.05). A mean of 0, 9, and 2.6 × 10(2) colony-forming units (CFUs) grew on culture from the implants treated with tigecycline, vancomycin, and PEG-PPS alone, respectively, and a mean of 1.2 × 10(2), 4.3 × 10(3), and 5.9 × 10(4) CFUs, respectively, on culture of the surrounding tissue (p < 0.05)., Conclusions: The PEG-PPS coating provides a promising approach to preventing periprosthetic infection. This polymer is novel in that it combines both passive and active antibiotic-release mechanisms. The tigecycline-based coating outperformed the vancomycin-based coating in this study., Clinical Relevance: PEG-PPS polymer provides a controlled, "smart" local delivery of antibiotics that could be used to prevent postoperative implant-related infections., (Copyright © 2016 by The Journal of Bone and Joint Surgery, Incorporated.)
- Published
- 2016
- Full Text
- View/download PDF